TYRA (Tyra Biosciences) Moat Score: 3/10 (As of Jun. 27, 2026)


TYRA Tyra Biosciences Inc TYRA
28 GF Score
Price $31.88
! 2 Warning Signs
View Full Analysis

What is Tyra Biosciences Moat Score?

Tyra Biosciences TYRA +3.07% 28 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,404 Biotechnology companies, Tyra Biosciences ranks better than 75.5% on this metric.

Tyra Biosciences has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Tyra Biosciences has No Moat: Tyra Biosciences Inc is in the early stages of development with limited market share and intellectual property. The company lacks significant customer switching costs and brand strength, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Tyra Biosciences might have No Moat - Very weak/transient advantages.

Tyra Biosciences  (NAS:TYRA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Tyra Biosciences Moat Score Related Terms

TYRA vs ZLAB, OCUL, AUPH: Moat Score Comparison

For the Biotechnology subindustry, Tyra Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyra Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's Moat Score falls into.


TYRA
28GF Score
Tyra Biosciences Inc TYRA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Tyra Biosciences (TYRA) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Tyra Biosciences ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Tyra Biosciences' Moat Score too high?
Tyra Biosciences' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Tyra Biosciences' value of 3 is 50% above this industry median. Based on the distribution chart, Tyra Biosciences ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Moat Score compare to ZLAB and OCUL?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #344 out of 1404 companies for Moat Score. This places Tyra Biosciences in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Tyra Biosciences' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tyra Biosciences's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tyra Biosciences's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tyra Biosciences Business Description

Address 2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score

Get the complete analysis for TYRA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.88
Price